Post-induction treatment for acute myeloid leukemia: something change?

• Verfasst von: Jaramillo Segura, Sonia [VerfasserIn]
• Verfasst von: Schlenk, Richard Friedrich [VerfasserIn]
• Titel: Post-induction treatment for acute myeloid leukemia: something change?
• Verf.angabe: Sonia Jaramillo, Richard F. Schlenk
• E-Jahr: 2021
• Jahr: 16 July 2021
• Umfang: 1-10$t10
• Fussnoten: Gesehen am 23.09.2021
• Titel Quelle: Enthalten in: Current oncology reports
• Ort Quelle: Philadelphia, Pa. : Current Science, Inc., 1999
• Jahr Quelle: 2021
• Band/Heft Quelle: 23(2021), 9, Artikel-ID 109
• ISSN Quelle: 1534-6269
• DOI: doi:10.1007/s11912-021-01092-0
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1771701609
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Until recently, improvement in terms of survival for patients with acute myeloid leukemia (AML) was achieved mostly in younger patients with dose intensification of conventional chemotherapy and a broadening use of allogeneic hematopoietic cell transplantation (allo-HCT) whereas the results remained dismal and very stable in patients older than 60 years. The current review highlights the recent developments in standard intensive post-remission chemotherapy, evidence for the use of recently approved agents, and discusses the relevance of measurable residual disease (MRD) measurement in treatment adaptation.